ReviewWorld journal of microbiology & biotechnology2026
Rethinking microbial biopesticide development and uptake.
Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biopesticides, pesticides based on living organisms and/or their bioactive compounds, are increasingly being used as alternatives and replacements to chemical and synthetic pesticides. This is largely due to human and environmental safety concerns, the emergence of pest resistance (collectively insect pests, weeds and diseases), and the move towards holistic pest and disease control approaches. While the number and diversity of agents used in biopesticides slowly increases, the approach to developing these products remains largely ad hoc, resulting in less than 10% success rate for development projects. Here we review the major characteristics of successful biopesticides. Our treatise focuses on the benefits of considering the entire development pathway and requirements of the intended product application before embarking on the costly process of biopesticide development and commercialisation. By a priori consideration of the characteristics of both the target pest and market, and the potential limitations of the candidate microorganism and/or its bioactives (e.g. environmental persistence, ease and cost of mass production), the development pipeline can be streamlined and targeted on projects with the greatest likelihood of success. We provide a detailed consideration of the key factors that underpin successful (or not) biopesticide development and provide decision trees to support the a priori process.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.